Meeting
2023 ASCO Annual Meeting
Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial.
Authors
Wenfeng Fang
Department of Medical Oncology, Sun Yat-sen University Cancer Center & State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China
Wenfeng Fang , Yuanyuan Zhao , Yan Huang , Yaxiong Zhang , Shaodong Hong , Yihua Huang , Hongyun Zhao , Yunpeng Yang , Shen Zhao , Gang Chen , Huaqiang Zhou , Yuxiang Ma , Ningning Zhou , Li Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05016544
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9105)
DOI
10.1200/JCO.2023.41.16_suppl.9105
Abstract #
9105
Poster Bd #
93
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2-positive gastric cancer or solid tumors: Safety and efficacy results from a phase Id trial.
First Author: Dan Liu
Poster
2018 ASCO Annual Meeting
A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer.
First Author: Zandong Yang
Poster
2015 ASCO Annual Meeting
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study.
First Author: Julien Mazières
Poster
2014 ASCO Annual Meeting
TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation.
First Author: Lucia Nogova